HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2013, Vol. 5 In 1999, the Food and Drug Administration (FDA) approved the use of dexmedetomidine as an alternative to GABA-mimetic drugs for ICU sedation (5) . Dexmedetomidine is an α 2 -adrenoceptor agonist, which has been shown to provide sedation and analgesia with minimal respiratory depression. This occurs via central nervous system receptors, particularly in the locus coeruleus, regulating memory, affect, awareness, and nociception (6) . Stimulation of these receptors also inhibits the release of norepinephrine, which may contribute to bradycardia and hypotension (7) . To date, investigators have not shown a consistent reduction in time to extubation for patients receiving dexmedetomidine. When compared to propofol in post-cardiac surgery patients, dexmedetomidine had no impact on time to extubation according to Barletta et al. (2) . Conversely, the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared with Midazolam) trial noted that the median time to extubation was 1.9 days shorter in dexmedetomidine versus midazolamtreated medical ICU patients requiring mechanical ventilation for more than 24 hours (8) . If earlier extubation of cardiac surgery patients could be demonstrated, there might be a justification for the additional expense of dexmedetomidine. Dexmedetomidine has analgesic properties and one could reasonably expect that the use of narcotics and non-narcotic analgesics would be lower in dexmedetomidine treated patients. If patients had less pain and received fewer narcotics, earlier mobility and improved cognition might occur immediately after surgery. We hypothesized that routine use of dexmedetomidine after cardiac surgery would decrease time to extubation, reduce analgesic use and improve early postoperative functional status.
MetHOdS
A retrospective analysis was conducted at Geisinger-Community Medical Center (GCMC) reviewing records of 99 patients admitted to the Cardiothoracic Intensive Care Unit (CTICU) for post-cardiac surgery care. The patients that did not receive dexmedetomidine were treated between January and March 2011, and the dexmedetomidine treated patients were operated on between February and May 2012. There were no other changes in surgeons, anesthesia staff, protocols or treatment strategies, other than the introduction of intravenous acetaminophen, between these two time periods. Intravenous acetaminophen replaced the oral route of administration at our site in late 2011. Patients with infective endocarditis, cardiogenic shock, prolonged ICU stay secondary to stroke or major intraoperative complication, and those who died during the index hospitalization were excluded. Charts were reviewed for patient characteristics, procedure type, postoperative complications, analgesic usage, and early postoperative functional status assessed by their ability to get out of bed. The Wright Center for Graduate Medical Education Institutional Review Board (WCG-ME-IRB: SRC032612) approved this study. Prior to February 2012, patients typically received no sedation, or rarely propofol or midazolam, beyond the short-acting narcotic based general anesthesia they received in the operating room. Starting in February 2012, cardiac surgical patients were given dexmedetomidine HCl infusion (loading dose of 1 mcg/kg over 10 minutes followed by maintenance doses ranging from 0.2 to 1.0 mcg/kg/hr) and benzodiazepine or propofol were no longer used as first-line sedatives. Thus, the study was retrospective and involved sequential groups of patients. The time to extubation was measured as the interval between arrival in the CTICU and removal from mechanical ventilation, based on the Society of Thoracic Surgeons (STS) National Database. The use of opioid analgesics during the first 48 hours was recorded as equi-analgesic doses of morphine. Thus, narcotics such as fentanyl and oxycodone were converted to equal potency. Non-narcotics such as ketorolac and acetaminophen were recorded as milligrams administered to patients during the first 48 hours postoperatively. Instances of bradycardia were defined as a heart rate lower than 55 beats per minute and hypotension was defined as a systolic blood pressure lower than 80 mmHg during the first 3 hours in CTICU, as documented in the care flow sheets. Glasgow Coma Scores over the first 48 hours postoperatively were also derived from the flow sheets. Functional status over the first 48 hours was determined by whether or not the patient was able to get out of bed and ambulate. Data collection took place at GCMC in the medical records department and via query of the STS computerized database. Patient identifiers except for a record number were removed from the Microsoft Excel Spreadsheet used to gather information. Results were summarized as mean ± standard deviation (SD) or as median (interquartile range) when appropriate. Statistical comparisons included Student's t-test, or median test and chi squared tests for continuous and categorical data, respectively, using spreadsheet software (Microsoft® Office Excel® 2007; Microsoft® Corporation; Redmond, WA). All P values 
ReSultS
We reviewed 52 records of patients treated prior to the introduction of dexmedetomidine in February 2012 (control group) and 47 records in the dexmedetomidine treated group. There were no self extubations or reintubations, and groups were similar with regards to need for additional sedatives ( Table 1 ). The two groups were similar with respect to age, gender, surgery type, and predicted risk of mortality (PROM) ( Table 1) . There was no statistically significant difference in time to extubation between groups. Among the control group, the median time to extubation was 3.9 (2.8-5.4) hours. In dexmedetomidine treated patients, median time was 4.7 (3.45-6.52) hours (P=.16) (Figure 1) . The safety profile did not differ significantly for patients who did or did not receive dexmedetomidine. The incidence of bradycardia in the control group was 3.8% while dexmedetomidine patients had an incidence of 2.1% (P=1.0). Hypotension did not occur in any patients in either cohort. For control patients, 25.0% were able to ambulate out of bed in the first 24 hours, and 14.9% of dexmedetomidine treated patients were out of bed during this time (P=.32). Glasgow Coma Scores of 15 on the first postoperative day occurred in 80.8% of patients in the control group and 87.2% of patients receiving dexmedetomidine (P=.42) ( Table 1) . There was no significant difference between control and dexmedetomidine patients with respect to opioid analgesic use. The median opioid use in morphine equivalents over the first 48 hours was 71 (46-105) mg in the control group and 102 (37-151) mg in dexmedetomidine patients (P=.09). On the day of surgery, control patients used 12 (0-19) mg of morphine equivalents while dexmedetomidine patients used 15 (2-23) mg (P=.90). On postoperative day 1, control patients used 34 (15-60) mg of morphine equivalents, while dexmedetomidine patients received 60 (15- 
dISCuSSIOn
This study suggested no difference in the incidence of bradycardia, incidence of hypotension, or the time of mechanical ventilation in patients receiving dexmedetomidine for sedation following cardiac surgery compared to patients that received no rou- tine postoperative sedation. Our findings are consistent with several previous studies that compared dexmedetomidine to placebo and suggested no differences in time of mechanical ventilation in patients receiving dexmedetomidine for sedation following cardiac surgery compared to patients that received no routine postoperative sedation. Our findings are consistent with several previous studies that compared dexmedetomidine to placebo and that suggested no differences in time to extubation for postsurgical patients (9, 10) . Although a prior study has suggested that the use of dexmedetomidine may even allow earlier extubation of cardiac surgery patients when compared to propofol (11), this finding was not confirmed by several studies suggesting that there was no difference in time to extubation between patients receiving dexmedetomidine or propofol in cardiac surgery patients (2, 12, 13). So-called "fast-track" cardiac surgery anesthetic techniques aim to extubate patients within a few hours postoperatively by using short-acting narcotics and sedatives (14) . GCMC adopted these techniques years ago with the goal of reducing CTICU length of stay as well of decreasing morbidity. It is reasonable to speculate that in ICUs that do not use our fast track protocols, intubation times might be shorter in patients receiving dexmedetomidine. In the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared with Midazolam) trial, the median time to extubation was 1.9 days shorter in dexmedetomidine versus midazolam for medical ICU patients who stayed on ventilators for more than 24 hours (8) . It is important to note that GCMC has consistently outperformed the national averages for cardiac surgery time to extubation. In 2010, 74.8% of GCMC post-cardiac surgery patients were extubated within 6 hours compared to the STS national average of 39.3%. Consequently, it is difficult to farther shorten time on mechanical ventilation in our population. With regard to analgesia, we recorded more narcotic, NSAID and acetaminophen use in dexmedetomidine patients, but only acetaminophen usage met statistical significance as a result from a shift in route of administration in the study period. Our observations regarding analgesics are in contrast to previous studies comparing dexmedetomidine with placebo in noncardiac surgical patients. Triltsch et al. recorded 58% less morphine usage with dexmedetomidine (9). Likewise, Martin et al. looked at 401 postsurgical patients, and found they required 69% less morphine when given dexmedetomidine as compared to placebo (10) . Similar results were observed when dexmedetomidine was compared to propofol after CABG surgery. Dexmedetomidine sedated patients received morphine 28% of the time, while propofol sedated patients required morphine 69% of the time. In that study, propofol treated patients required a total dose of morphine which was 4 times that of dexmedetomidine treated patients (13) . However, our observation that dexmedetomidine was not "narcotic-sparing" is consistent with several other studies. It has been suggested that dexmedetomidine increased the use of opioids for patients treated with this sedative as compared to propofol (15) . Prior work also reported that dexmedetomidine increased morphine use from 3.6% to 39.3% and ketorolac use from 3.6% to 25% over propofol in post-cardiac surgery patients in a small (n=28) population (14) . Thus, the role of dexmedetomidine in reducing narcotic and non-narcotic analgesia usage is not clearly defined yet. We found that hypotension and bradycardia occurred very rarely in patients sedated with dexmedetomidine. The most commonly reported side effect of dexmedetomidine was hypotension (16) . Studies have also shown that when compared to placebo in ventilated postsurgical patients, dexmedetomidine is associated with lower heart rates (9). Hypotension was more common in dexmedetomidine than propofol, 36% versus 24% (P=.11) among 300 post-CABG patients (13) . Randomized control trials, particularly the SEDCOM trial, found that dexmedetomidine treated patients were more likely to develop bradycardia than those receiving midazolam (8) , with no more hypotension than with morphine (17) . In a meta-analysis of dexmedetomidine effects, a significantly increased risk of bradycardia occurred when a loading dose and a high maintenance dose (>0.7 µg kg -1 h -1
) were used (18). Dexmedetomidine did not significantly impact the functional status of our patients as measured by the ability to get out of bed and ambulate on postoperative day 0. Other studies utilized The Richmond Agitation-Sedation Scale (RASS), the Ramsay Sedation Scale (RSS), or the Confusion Assessment Method for the ICU (CAM-ICU) to assess alertness or delirium. While the RASS is validated for assessing ICU sedation in those who are mechanically ventilated (19), we were unable to utilize these tools. Thus, we were not able to show that dexmedetomidine allowed patients to be more awake, less sedated, and more functional shortly after heart surgery. A potential benefit of dexmedetomidine may be the avoidance of early postoperative confusion or agitation. Clinicians have described patients treated with dexmedetomidine as "calmer" and less likely to wake up suddenly and attempt to self-extubate. This could be important for patient safety and satisfaction. Dexmedetomidine treated patients are generally easily aroused as opposed to being deeply sedated. However, this "tranquilly sedated" state is difficult to quantify, and we were unable to do so in our retrospective analysis. It is possible to achieve the same level of sedation with other drugs used at the appropriate doses. There were several limitations to this study. First, the population size for the non-dexmedetomidine and dexmedetomidine study groups were small, 52 patients and 47 patients, respectively. In addition, there are limitations related to any chart review as a consequence of variation in the charting by clinical staff. These limitations left gaps in our ability to robustly characterize some patient outcomes. Furthermore, patients with serious complications and those who died were excluded from the data-analysis. In conclusion, in this retrospective study we found no significant difference between patients receiving and not receiving dexmedetomidine with regards to time on mechanical ventilation and to the incidence of bradycardia and hypotension.
